Musa Mayer of New York City was diagnosed with breast cancer 22 years ago. Since then, she has become a patient advocate and author of the highest integrity. She also continues to serve as a patient representative with several Food and Drug Administration (FDA) committees, with a vote on whether to approve new cancer drugs.
In this interview, Musa gives us an insider’s view into the way the FDA evaluates cancer drugs. Why does the approval of cancer drugs take so long? Why are some seemingly promising drugs not approved?
Musa also gives reasonable expectations for clinical trials and explains their role in the approval process. She gives us hope of how the linking between new cancer diagnostic tests and new drugs could accelerate the approval of medications.
Patient Representative and ConsultantMusa Mayer is a 22-year survivor, advocate and author of three books on breast cancer, including "Advanced Breast Cancer: A Guide to Living with Metastatic Disease." Her articles on breast cancer and advocacy frequently appear in magazines, newsletters, websites and scientific journals, and she serves on a number of advisory and editorial boards, as well as steering committees and data... more >